Carlos Pérez‐Plasencia

A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors

Myrna Candelaria, Dolores Gallardo‐Rincón, Claudia Arce et al. · Annals of Oncology · 2007 · 252 citations

Medicine, Oncology, Pharmacology +17

Cancer-initiating cells derived from established cervical cell lines exhibit stem-cell markers and increased radioresistance

Jacqueline López, Adela Poitevin, Veverly Mendoza-Martínez et al. · BMC Cancer · 2012 · 211 citations · Full text

Medicine, Cell Biology, Oncology +16

A Proof-Of-Principle Study of Epigenetic Therapy Added to Neoadjuvant Doxorubicin Cyclophosphamide for Locally Advanced Breast Cancer

Claudia Arce, Carlos Pérez‐Plasencia, Aurora González‐Fierro et al. · PLoS ONE · 2006 · 144 citations · Full text

Medicine, Oncology, Pharmacology +16

Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines

Alma Chávez‐Blanco, Carlos Pérez‐Plasencia, Enrique Pérez‐Cárdenas et al. · Cancer Cell International · 2006 · 142 citations · Full text

Medicine, Oncology, Pharmacology +15

Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study

Alma Chávez‐Blanco, Blanca Segura‐Pacheco, Enrique Pérez‐Cárdenas et al. · Molecular Cancer · 2005 · 128 citations · Full text

Medicine, Oncology, Pharmacology +17